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Abstract
Objective To evaluate the impact of state supported overdose education
and nasal naloxone distribution (OEND) programs on rates of opioid
related death from overdose and acute care utilization in Massachusetts.
Design Interrupted time series analysis of opioid related overdose death
and acute care utilization rates from 2002 to 2009 comparing
community-year strata with high and low rates of OEND implementation
to those with no implementation.
Setting 19 Massachusetts communities (geographically distinct cities
and towns) with at least five fatal opioid overdoses in each of the years
2004 to 2006.
Participants OEND was implemented among opioid users at risk for
overdose, social service agency staff, family, and friends of opioid users.
InterventionOEND programs equipped people at risk for overdose and
bystanders with nasal naloxone rescue kits and trained them how to
prevent, recognize, and respond to an overdose by engaging emergency
medical services, providing rescue breathing, and delivering naloxone.
Main outcomemeasures Adjusted rate ratios for annual deaths related
to opioid overdose and utilization of acute care hospitals.
Results Among these communities, OEND programs trained 2912
potential bystanders who reported 327 rescues. Both community-year
strata with 1-100 enrollments per 100 000 population (adjusted rate ratio
0.73, 95% confidence interval 0.57 to 0.91) and community-year strata
with greater than 100 enrollments per 100 000 population (0.54, 0.39 to
0.76) had significantly reduced adjusted rate ratios compared with
communities with no implementation. Differences in rates of acute care
hospital utilization were not significant.
ConclusionsOpioid overdose death rates were reduced in communities
where OEND was implemented. This study provides observational
evidence that by training potential bystanders to prevent, recognize, and
respond to opioid overdoses, OEND is an effective intervention.
Introduction
Poisoning, nine out of 10 of which are related to drug
overdoses,1 has surpassedmotor vehicle crashes to be the leading
cause of death by injury in the United States.2 Overdose is also
a major cause of death in Canada,3 Europe,4 Asia,5 6 and
Australia.7 In the United States, increases in fatal overdose since
the mid-1990s have been driven by the growth in prescriptions
for opioid analgesics8 and their non-medical use.9 10 Opioid
related emergency department visits and admissions to hospital
have increased over the same period.11 In Massachusetts, since
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2005, annual opioid-related overdose deaths have exceeded
motor vehicle deaths.12
Strategies have been implemented to deal with opioid overdose.
Prescription drug monitoring programs,13 prescription drug take
back days, safe opioid prescribing guidelines, and education
programs seek to reduce opioid misuse and/or diversion to
people who do not have prescriptions. While these strategies
are promising, none has been demonstrated in clinical trials or
controlled observational studies to reduce overdose rates.
Methadone maintenance treatment14 15 and supervised injection
facilities16 are strategies associated with decreased fatalities
from overdose in controlled studies.
Naloxone is an opioid antagonist that reverses the effects of
opioid overdose. Overdose education and naloxone distribution
(OEND) programs tackle overdose by educating people at risk
for overdose and bystanders in how to prevent, recognize, and
respond to an overdose. Participants in the program are trained
to recognize signs of overdose, seek help, rescue breathe, use
naloxone, and stay with the person who is overdosing. From
1996 through 2010, over 50 000 potential bystanders were
trained by OEND programs in the United States, resulting in
over 10 000 opioid overdose rescues with naloxone.17 In March
2012, the United Nations Commission on Narcotic Drugs
recognized overdose as a global public health issue that warrants
focus by theWorld Health Organization andmember countries,
including the use of naloxone for the prevention of opioid
overdose.18 Studies of OEND programs have demonstrated
feasibility,19-22 increased knowledge and skills,23-26 and a
concomitant reduction in fatal overdoses after initiation of
OEND.27 28A controlled study of OEND and overdose rates has
not been completed. Implementation of OEND inMassachusetts
in communities with a high burden of opioid overdose created
the opportunity to study the impact of OEND on opioid related
fatal overdose and acute care hospital utilization rates, using
high burden communities with low or noOEND implementation
as concurrent controls.
Methods
We conducted an interrupted time series analysis of annual
opioid related rates of overdose fatalities and utilization of acute
care hospitals comparing communities and years where OEND
was implemented with those where it was not. The analysis was
conducted at the city/town level. Massachusetts consists of 351
geographically distinct cities and towns (referred to as
communities). We included the 19 communities with five or
greater opioid related unintentional or undetermined intentional
fatal poisonings in each year from 2004 to 2006, which were
the years immediately preceding the implementation of OEND.
The Massachusetts OEND program
In 2006-07, two community public health agencies began
providing OEND.20 The Massachusetts Department of Public
Health expanded the program to four more organizations in
2007 and two more in 2009. These agencies, which provided
HIV education and prevention services to substance users,
providedOEND to potential overdose bystanders through trained
non-medical public health workers under a standing order from
the OENDmedical director. Potential overdose bystanders were
opioid users at risk for overdose, as well as social service agency
staff, family, and friends of opioid users. Training sites included
syringe access programs, HIV education drop-in centres,
addiction treatment programs, emergency and primary healthcare
settings, and community meetings, such as support groups for
family members of opioid users.
Training curriculums were initially developed by the Harm
Reduction Coalition and the Chicago Recovery Alliance,19-27
and adapted for nasal naloxone. OEND trainers completed a
four hour course, knowledge test, and two trainings of potential
bystanders supervised by a master trainer. The training of
program participants by OEND trainers were conducted in
groups or individually, took as little as 10 minutes for enrollees
with substantial pre-existing knowledge and as much as 60
minutes for groups that generated discussion or had enrollees
without prior knowledge of overdose, and were tailored to the
training setting. Key elements included minimizing the risk of
overdose by reducing polysubstance misuse (for example,
concomitant alcohol, benzodiazepine, or cocaine), accounting
for reduced tolerance after abstinence, and not using alone;
recognizing overdose by assessing for unresponsiveness and
decreased respirations; and responding to an overdose by seeking
help, providing rescue breathing, administering nasal naloxone,
and staying with the person until medical personnel arrived or
the person recovered. Trainings concluded with enrollees
demonstrating proper assembly of the naloxone device and how
naloxone should be administered. Naloxone rescue kits
contained instructions, two prefilled syringes with 2 mg/2 mL
naloxone hydrochloride, and twomucosal atomization devices.
Two doses were included in case one dose was not sufficient
or if overdose symptoms returned, because the half-life of many
opioids is longer than that of naloxone.
Data collection and measures
Fatal opioid overdose rates
For the fatal opioid overdose outcome, we calculated rates of
unintentional and undetermined intentional opioid related drug
poisonings by community of residence using in-state occurrent
deaths from the electronic database maintained by the
Massachusetts Registry of Vital Records and Statistics,
Massachusetts Department of Public Health. Death certificates
on fatal poisonings in Massachusetts are completed through a
single centralized, statewide office of the chief medical
examiner, where they are required by law to be reported. Opioid
related deaths were defined by ICD-10 (international
classification of diseases, 10th revision) codes indicating
unintentional or undetermined intentional poisoning (X40-X44,
Y10-Y14) in the underlying cause of death field and an opioid
specific T code of T40.0-T40.4 and/or the narcotic T code T40.6
in any of the multiple cause of death fields. The use of T40.6
to identify opioid related deaths is recommended in jurisdictions
where a high proportion of deaths with this code is opioid
specific.29 An unpublished review of 2007Massachusetts death
certificate literals indicated that T40.6 had a positive predictive
value of 98% for an opioid related death. Furthermore, 96.7%
of unintentional or undetermined intentional deaths by poisoning
in Massachusetts in 2007 received at least one ICD-10 code in
the range (T36-T50.8), indicating that specific information on
agent or class of agent was present on death certificates for
nearly all drug related deaths.
Opioid overdose related acute care hospital
utilization rates
We used the Massachusetts inpatient hospital and outpatient
emergency department discharge databases administered by the
Massachusetts Division of Health Care Finance and Policy to
quantify acute care hospital inpatient and emergency department
discharges associated with opioid poisoning by city or town of
residence. Submission of external cause of injury codes (E
codes) are required by state regulation on all cases with a
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principle diagnosis of injury or poisoning, ensuring high quality
data for state injury surveillance. Cases were defined as
discharges having an ICD-9-CM (international classification of
diseases, ninth revision, clinical modification) code of one or
more of the following opioid related discharge diagnosis or E
codes: 965 (.00, .01, .02, .09), E850 (.0, .1, .2). We excluded
those cases receiving an E code indicating that the poisoning
was the result of intentional self harm, assault, an adverse effect
of a drug in therapeutic use, or legal intervention. To avoid
duplicate counts with the fatality measure we excluded deaths
occurring during the hospital event from this outcome.
Descriptive variables from enrollment and
naloxone rescue attempt questionnaires
TheMassachusetts Department of Public Health OENDprogram
database included information from program questionnaires
collected at both enrollment and whenever an enrollee requested
an additional naloxone kit. The completed questionnaires were
scanned by form reading software and entered into the program
database. At enrollment, zip code of residence, drug use history,
and overdose history were collected. We defined users as
participants who reported active use or being in treatment or in
recovery. Non-users were all other participants, typically social
service agency staff, family, and friends of opioid users. A
questionnaire was completed when a participant requested a
naloxone refill because naloxone had been used during an
overdose rescue. Staff were trained to define an overdose when
administering the questionnaire as an episodewhen an individual
was unresponsive and had signs of respiratory depression after
using substances. We only counted events where participants
reported their own overdose rescue attempts if another person
administered the naloxone. Self administered naloxone was
rarely reported and was not counted as a rescue attempt because
a person able to self administer the drug was not considered to
be unresponsive. We considered naloxone to be successfully
administered if the person’s unresponsiveness and respiratory
depression improved. Other descriptive variables included the
zip code of the place in which the overdose occurred,
relationship to the person who overdosed, setting (public or
private), number of naloxone doses used, whether naloxone was
successful, emergency medical system involvement, rescue
breathing, and staying with the person who overdosed.
Independent variables:OENDenrollment rates
To determine the cumulative enrollment rates for the 19
communities with high overdose burdens we used the
community of residence based on the zip code of residence on
the enrollment questionnaire. We modeled OEND
implementation in two ways. Firstly, we categorized OEND
implementation into three groups within each year based on the
median cumulative enrollment rate (relative model). Groups
included community-year strata with no implementation, those
below the median (low implementers), and community-year
strata with enrollment rates above the median (high
implementers). Secondly, to determine if an absolute population
density of enrollment was associated with overdose rates, we
categorized communities in each year into three categories based
on cumulative enrollment rate levels of no implementation,
1-100 per 100 000 population and >100 per 100 000 population
(absolute model). In the models we used enrollment cut points
of 0, 1-75, >75 and in sensitivity analyses cut points of 0, 1-150,
and >150.
Covariates
To account for geographic differences in overdose risk, we
adjusted our analyses for demographics.We linearly interpolated
community specific data (age, sex, race or ethnicity, poverty)
for each year from the community specific 200030 and 201031
US Census Bureau data.
We used data from the Massachusetts prescription drug
monitoring program to adjust for opioid prescriptions to “doctor
shoppers,” defined as individuals who had schedule II opioid
prescriptions from four or more prescribers and filled
prescriptions at four or more pharmacies in a 12 month period.32
We calculated the proportion of schedule II opioid prescriptions
dispensed to doctor shoppers per total opioid prescriptions for
each community-year stratum.
Inpatient medically supervised withdrawal (detox) results in a
period of abstinence that can increase overdose rates,33 34whereas
engagement in methadone treatment results in decreased rates
of overdose.14 Office based buprenorphine treatment expanded
during the study period. To adjust for these three treatment
services, we calculated population rates of methadone
maintenance, buprenorphine maintenance, and detox events for
each community-year stratum using data from theMassachusetts
Department of Public Health Bureau of Substance Abuse
Services treatment database. Any treatment program licensed
by and contracted with the Substance Abuse Services was
required to report admission and discharge information.
We accounted for linear trends over the study period by using
a time variable T, expressed as 1 for the index year 2002 and
increasing in integer increments for each year of the study
period.
Statistical analysis
For the interrupted time series we used the annual rates of fatal
opioid related overdose and acute care hospital utilization
associated with non-fatal opioid overdose by community of
residence for the units of analysis. The denominators were the
community population based on US Census estimates. Based
on the independent variable definitions, we coded individual
community-year combinations with an indicator variable
denoting “implementation.” As in other studies of injury trends35
and program implementation,36 we used Poisson regression
models to test our hypotheses that those community-year strata
with higher implementation would have lower rates. We
modeled rates directly with a log-linear statistical model by
including counts as the dependent outcome and population at
risk as an offset term. We controlled for community level
covariates by including them in the model. All hypothesis tests
used a significance level (α) of 0.05. We performed regression
diagnostics, including quasi likelihood information criteria,37 to
assess goodness of fit. Based on these, we chose first order
autoregressive covariance structure to account for the
interdependence of repeated measures.
To determine whether our findings were specific to overdose
outcomes or due to an unmeasured health system effect, such
as healthcare reform, we conducted additional sensitivity
analyses. We refit the adjusted Poisson fatal overdose models
substituting fatal opioid overdose rates with overdose death to
cancer death rate ratios for each community-year stratum using
data from the Massachusetts Registry of Vital Records and
Statistics.We also refit models substituting acute care utilization
rates associated with non-fatal opioid related poisoning with
non-fatal opioid related poisoning or non-fatal motor vehicle
traffic related injury rate ratio for each community-year
stratum.38 To define cancer deaths we used ICD-10 codes
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C000-C979, representing malignant neoplasms. We defined
cases of non-fatal motor vehicle traffic related injury by
discharge diagnoses with an ICD-9-CM code of 800-909.2,
909.4, 909.9, 910-994.9, 995.5-995.59, 995.80-995.85 and an
E code, E810-E819 (.0-.9), for unintentional motor vehicle
traffic crash. All analyses were done using SAS version 9.3.
Results
Table 1⇓ lists the characteristics of the 19 communities in
Massachusetts. Thesemake up about 30% of the state population
and contribute almost half of Massachusetts’ fatal opioid
overdoses and acute care hospital utilizations for non-fatal opioid
overdose.
Between 18 September 2006 and 31 December 2009 in
Massachusetts, 4857 individuals were enrolled in OEND and
545 naloxone rescue attempts reported. Among the 19
communities meeting the study criteria, 2912 individuals were
enrolled (table 2⇓) and 327 rescue attempts made (table 3⇓).
The experience of witnessing an overdose was common among
both users and non-users at enrollment. Users commonly had
a personal history of overdose and reported detoxification
treatment and incarceration in the past year.
Of 327 rescue attempts using naloxone reported by 212
individuals, 87% (286/327) were reported by users. Most rescue
attempts occurred in private settings. The rescuer and the person
who overdosed were usually friends. Naloxone was successful
in 98% (150/153) of the rescues attempts. For the three rescue
attempts where naloxone was not successful, the people who
overdosed received care from the emergency medical system
and survived.
Among the 19 communities studied, none had any OEND
implementation in 2002-05, 7 had some implementation in 2006
(median of 3 enrollees per 100 000 population), 14 had some
in 2007 (median of 7 enrollees per 100 000), and all 19 had
OEND implementation in 2008-09 (medians of 55 and 142,
respectively). Figures 1⇓ and 2⇓ show the unadjusted rates of
unintentional opioid related overdose deaths and acute acre
utilizations, respectively, categorized by no, low and high
implementation.
Adjusted models: OEND implementation and
fatal overdose rates
Generally, opioid related death rates were reduced in those
communities that implemented OEND compared with
community-year strata with no OEND implementation. In the
adjusted model based on absolute numbers of enrollments, both
the low implementer community-year strata with 1-100
enrollments per 100 000 population (adjusted rate ratio 0.73,
95% confidence interval 0.57 to 0.91) and the high implementer
community-year strata with greater than 100 enrollments per
100 000 population (0.54 0.39 to 0.76) had significantly reduced
adjusted rate ratios in a dose related fashion compared with
communities with no implementation (table 4⇓, for full models
see supplementary tables 4a and 4b). In sensitivity analyses,
using alternative cut points of 75 enrollments and 150
enrollments per 100 000 population, rate ratios were similar.
For the adjusted model that used the median enrollment rates,
overdose death rates were reduced, but significantly so only for
the low implementer group (0.71, 0.57 to 0.90).
Adjusted models: OEND implementation and
opioid related non-fatal acute care hospital
utilizations
For non-fatal opioid overdose related acute care hospital
utilizations, there was no statistically significant association
between the communities based on absolute or relative
enrollment rates compared with no implementation (table 5⇓,
for full models see supplementary tables 5a and 5b). In
sensitivity analyses, rate ratios were similar then alternative cut
points of 75 enrollments and 150 enrollments per 100 000
population were used.
Control models
Models in which the opioid related overdose fatality outcome
were substituted for the ratio of opioid related overdose death
rates over the cancer related death rates had statistically
significant associations in a similar pattern to the original
models. Thus the associations of OEND implementation with
fatal overdose rates occurred independently of any effects related
to cancer fatalities (see supplementary table 6). The similar
procedure with motor vehicle crash injuries and acute care
utilization models showed no association of OEND
implementation on rates, independent of motor vehicle injuries
(see supplementary table 7).
Discussion
Between 2006 and 2009,Massachusetts overdose education and
nasal naloxone distribution (OEND) programs trained thousands
of people who use opioids and their families, friends, and social
service providers to prevent, recognize, and respond to
overdoses, resulting in hundreds of reported rescue attempts.
Compared with no implementation, both low and high
implementation of OEND were associated with lower rates of
opioid related deaths from overdose, when adjusted for
demographics, utilization of addiction treatment, and doctor
shopping (schedule II opioid prescriptions from ≥4 prescribers
and filled prescriptions at ≥4 pharmacies in a 12month period).
These associations were seen independently of effects related
to cancer death rates. Rates of opioid related visits to an
emergency department and admission to hospital were not
significantly different in communities with low or high
implementation of OEND.
Strengths and limitations of the study
The major strength of this study was the interrupted time series
analysis approach that capitalized on naturally occurring
geographic and time controls owing to the broad but variable
implementation of OEND inMassachusetts. The study included
years 2002-09, yet OEND implementation began in some
communities in 2006 and gradually expanded through 2009.
Thus the “no implementation” comparison group included all
19 communities for 2002-05 and only those communities with
no enrollment in 2006-09. The pre-implementation and
post-implementation comparisons (no versus any
implementation) hinged on when implementation started in an
individual community. Further, we investigated effects among
those communities with high and low implementation. When
implementation was defined in a relative manner, based on the
median implementation rate in each year, there was an
association in the expected direction, but there did not seem to
be an implementation dose relation with opioid related overdose
death rates. Yet when implementation was defined in an absolute
manner based on the cumulative number of enrollments per
population, there was both an association in the expected
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direction and a dose relation with death rates. A community’s
absolute enrollment rate had a stronger impact on overdose
death rates than the relative enrollment rate. We included both
a disease specific mortality and healthcare utilization outcome.
We repeated the analyses with substitute outcomes that
incorporated unrelated conditions to check if there was some
system level effect in how deaths or acute care utilizations were
coded that could account for our findings.
Using an observational approach, this study cannot prove
definitively that OEND caused a reduction in opioid related
overdose death rates. This study had several other limitations
to the data available, which we attempted to address. Firstly,
the true population of opioid users in each community was not
known. To account for this we adjusted analyses for differences
in demographics, use of addiction treatment, and proportion of
prescriptions to doctor shoppers. Secondly, opioid overdose
fatalities may have been misclassified. However, in
Massachusetts the medical examiner’s office is centralized, with
each death certificate processed through the same system.
Thirdly, visits to emergency departments and admissions to
hospitals associated with opioid poisoning were defined based
on administrative discharge codes. Although discharge codes
are a blunt measure of cause for utilization, systematic
directional misclassification has not been found in other
studies.39 Fourthly, overdoses may have occurred in clusters,
which could result in the assumption that spurious events
represent a trend. However, this study was conducted over eight
years in 19 communities. Fifthly, we createdmeasures of OEND
implementation consistent with our conception of how OEND
may impact on rates of fatal overdose and acute care utilization,
but they have not been validated in other populations. We tested
several levels of OEND implementation and found similar
patterns of association with opioid related overdose and acute
care utilization rates. Lastly, the description of reported overdose
rescue attempts was limited to only those rescues reported back
to programs, and thus was likely underreported.
Interpretation
This study provides observational evidence that OEND is an
effective public health intervention to address increasing
mortality in the opioid overdose epidemic by training potential
bystanders to prevent, recognize, and respond to opioid
overdoses. OEND implementation seemed to have a dose related
impact, where the higher the cumulative rate of OEND
implementation, the greater the reduction in death rates. While
OEND programs should reduce visits to emergency departments
and hospital admissions by preventing overdoses in the first
place, they may also increase visits by encouraging bystanders
to engage the emergency medical system, which is an explicit
part of OEND curriculums. This balance of reducing and
increasing the use of the emergency medical system may be
why no association was found for acute care utilization.
Implications for research, policy, and practice
Some research issues follow from this study. Because OEND
targets not only the overdose risk behaviours of the trainee but
empowers trainees to intervene in another person’s overdose,
it makes a fuller impact at the community level rather than at
the individual level. Therefore, an individual level prospective
clinical trial is unlikely to capture the community level effect
of OEND unless it uses a multisite or social network design or
measures community level outcomes to account for the network
effects and potential contamination between individual
participants. It is also important to determine howOEND should
be tailored and implemented among different populations to
maximize effectiveness. In Massachusetts, similar OEND
curriculums have been delivered to heroin users, prescription
opioid users, patients in emergency departments, people who
are incarcerated, family members, social service providers,
police officers, and fire fighters.
This study provides strong support for the public health agency
policy and community based organisation practice to implement
and expand OEND programs as a key way to address the opioid
overdose epidemic. Two features of the Massachusetts OEND
programs that supported broad implementation include the use
of an nasal naloxone delivery device and the use of a standing
order issued by the health department, which allowed
non-medical personnel to deliver OEND. These features may
enable broader implementation with greater impact as more
communities implement OEND.
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Tables
Table 1| Characteristics of 19 Massachusetts communities* with high opioid overdose burden. Values are percentages unless stated
otherwise
Communities (n=19)Characteristics












Treatment events per 100 000 people, 2009:
630.0Inpatient detoxification
161.8Methadone maintenance
41.5Stated funded buprenorphine maintenance
10.9Opioid prescriptions to doctor shoppers†
*Geographically distinct cities and towns.
†Schedule II opioid prescriptions dispensed to doctor shoppers (individuals with schedule II opioid prescriptions from ≥4 prescribers and filled prescriptions at ≥4
pharmacies in 12 month period) per total opioid prescriptions dispensed.
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Table 2| Characteristics of potential overdose bystanders trained in overdose education and nasal naloxone distribution program in 19
Massachusetts communities*, 2006-09. Numbers are percentages (number/number in group) unless stated otherwise
Non-users (n=905)Users† (n=2007)All enrollees (n=2912)Characteristics
42.6 (13.0)36.1 (11.1)38.1 (12.1)Mean (SD) age (years)
58.3 (523/897)38.1 (751/1973)44.4 (1274/2870)Female and male to female transgender
Race or ethnicity:
65.8 (592/900)71.2 (1421/1996)69.5 (2013/2896)White, non-Hispanic
14.3 (129/900)17.0 (339/1996)16.2 (468/2896)Hispanic
14.6 (131/900)8.7 (174/1996)10.5 (305/2896)Black or African American, non-Hispanic
5.3 (48/900)3.1 (62/1996)3.8 (110/2896)Other, non-Hispanic
NA47.3 (950/2007)—Detox in past year
NA27.1 (460/1695)—Incarceration in past year
NA54.0 (976/1808)—Lifetime history of overdose
NA60.0 (503/838)—Received naloxone at last overdose
56.5 (465/823)80.8 (1571/1944)73.6 (2036/2767)Overdose witnessed ever
3.1 (28/905)9.2 (184/2007)7.3 (212/2912)Reported at least one overdose rescue
NA=not available.
Denominators less than total number for each group are due to missing information.
*Geographically distinct cities and towns.
†Enrollees who self reported active substance misuse, currently engaged in treatment or in recovery at enrollment.
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Table 3| Overdose rescue attempts reported by bystanders trained in the overdose education and nasal naloxone distribution program in
19 Massachusetts communities*, 2006-09
% (No/No in group)
Variables Non-users (n=41)Users† (n=286)All enrollees (n=327)
Status of person who overdosed:
43 (16/37)72 (200/276)69 (216/313)Friend
41 (15/37)12 (34/276)16 (49/313)Partner or family
16 (6/37)9 (26/276)10 (32/313)Stranger
0 (0/37)6 (16/276)5 (16/313)Self
Overdose setting:
70 (28/40)80 (221/277)78 (249/317)Private
30 (12/40)20 (56/277)22 (68/317)Public
No of doses used:
50 (20/40)48 (129/272)48 (149/312)1
50 (20/40)48 (130/272)48 (150/312)2
0 (0/40)5 (13/272)4 (13/312)≥3
100 (20/20)98 (130/133)98 (150/153)Naloxone successful
76 (31/41)26 (75/285)33 (106/326)911 called or emergency personnel present
44 (18/41)37 (105/286)38 (123/327)Rescue breathing performed
83 (34/41)90 (253/280)89 (287/321)Stayed with victim until alert and awake or help arrived
Denominators less than total number for each group are due to missing information.
*Geographically distinct cities and towns.
†Enrollees who self reported active substance use, currently engaged in treatment or in recovery at enrollment.
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Table 4| Models of overdose education and nasal naloxone distribution implementation and unintentional opioid related overdose death
rates in 19 communities* in Massachusetts, 2002-09
P valueAdjusted rate ratio† (95% CI)Rate ratioCumulative enrollments per 100 000 population
Absolute model:
ReferenceReferenceNo implementation
<0.010.73 (0.57 to 0.91)0.93Low implementation: 1-100 enrollments
<0.010.54 (0.39 to 0.76)0.82High implementation: >100 enrollments
Relative model:
ReferenceReferenceNo implementation
<0.010.71 (0.57 to 0.90)0.85Low implementation: <median
0.060.78 (0.60 to 1.01)1.00High implementation: >median
*Geographically distinct cities and towns.
†Adjusted for city/town population rates of age under 18, male, race or ethnicity (Hispanic, white, black, other), below poverty level, medically supervised inpatient
withdrawal treatment, methadone treatment, Bureau of Substance Abuse Services funded buprenorphine treatment, prescriptions to doctor shoppers (individuals
with schedule II opioid prescriptions from ≥4 prescribers and filled prescriptions at ≥4 pharmacies in 12 month period), and year.
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Table 5| Models of overdose education and nasal naloxone distribution implementation and opioid overdose related acute care hospital
utilizations in 19 communities* in Massachusetts, 2002-09
P valueAdjusted rate ratio† (95% CI)Rate ratioCumulative enrollments per 100 000 population
Absolute model:
ReferenceReferenceNo implementation
0.40.93 (0.80 to 1.08)1.00Low implementation: 1-100 enrollments
0.40.92 (0.75 to 1.13)1.06High implementation: >100 enrollments
Relative model:
ReferenceReferenceNo implementation
0.20.90 (0.76 to 1.07)0.96Low implementation: <median
1.01.00 (0.86 to 1.16)1.10High implementation: >median
*Geographically distinct cities and towns.
†Adjusted for city/town population rates of age under 18, male, race or ethnicity (Hispanic, white, black, other), below poverty level, medically supervised inpatient
withdrawal treatment, methadone treatment, Bureau of Substance Abuse Services funded buprenorphine treatment, prescriptions to doctor shoppers (individuals
with schedule II opioid prescriptions from ≥4 prescribers and filled prescriptions at ≥4 pharmacies in 12 month period), and year.
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Figures
Fig 1 Unadjusted unintentional opioid related overdose death rates in 19 communities with no, low, and high enrollment in
overdose education and nasal naloxone distribution program in Massachusetts, 2002-09
Fig 2 Unadjusted opioid related acute care hospital utilization rates in 19 communities with no, low, and high enrollment in
overdose education and nasal naloxone distribution program in Massachusetts, 2002-09
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